R&D | May 25, 2026
Sumitomo Pharma unveils new COURAGE & OPTYX data at AUA 2026
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
The approval was granted by Agenzia Italiana del Farmaco
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Subscribe To Our Newsletter & Stay Updated
